highlights from Innate Pharma’s R&D update

On April 10, 2014 Innate Pharma reported its clinical development plan for IPH2201 (Press release Innate Pharma, APR 10, 2014, View Source [SID:1234500393]). Clinical trials are expected to begin in 2014, and three indications have been prioritized:

Head and Neck cancer:
* Single-arm single-agent Phase II trial of IPH2201 in patients with metastatic or recurrent platinum refractory squamous cell carcinoma of the Head and Neck;
* Single-arm Phase II trial of IPH2201 combined with cetuximab in patients with metastatic or recurrent platinum refractory squamous cell carcinoma of the Head and Neck;

Chronic Lymphocytic Leukemia (CLL):
* Single-arm Phase II trial of IPH2201 combined with ibrutinib in relapsed/refractory CLL patients;

Ovarian cancer:
* Single-arm single-agent Phase II trial of IPH2201 in platinum resistant ovarian cancer patients;

* Single-arm Phase II trial of IPH2201 combined with physician choice in platinum resistant ovarian cancer patients.